GSD Devonian Health Group Inc.
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name. Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Devonian Health Group (CVE: GSD)
›
Devonian Health Group (CVE: GSD) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 6.750 CAD on 19 November 2026, down 55.0% over 52 weeks. Its 52-week range is 0.1900 CAD to 15.00 CAD: the price is 55.0% below the high and 3452.6% above the low.
Its market capitalisation is 18.77M CAD.
Devonian Health Group reports return on equity of -65.8%, an operating margin of -206.7% and revenue down 97.6% year over year.
It holds more cash than debt, a net cash position of 579.39K CAD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 26 November 2026.